AXSOME THERAPEUTICS, INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$638M
Cost of Revenue
$47M
R&D
$183M
SG&A
$571M
D&A
$503K
Operating Income
$-167M
EBITDA
$-166M
Interest Expense
$-16M
Interest Income
$9M
Other Income/Expense
$-42M
Pretax Income
$-184M
Tax Provision
$-530K
Net Income
$-183M
Operating Margin
-26.1%
Net Margin
-28.7%
Effective Tax Rate
0.3%
Deferred Tax Assets
$34K
Deferred Tax Liabilities
—
DTA Valuation Allowance
$316M
Tax Credit Carryforwards
$25M
NOL Carryforwards
$578M
ETR (Continuing Operations)
0.3%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-2.1%
ETR Foreign Differential (pp)
-6.3%
Operating Lease Cost
$5M
Revenue YoY Variation
65.5%
Income YoY Variation
40.6%